Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Payment, Tax Withholding, Share-Based Payment Arrangement

Payment, Tax Withholding, Share-Based Payment Arrangement at other companies

Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
——

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's payment, tax withholding, share-based payment arrangement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's payment, tax withholding, share-based payment arrangement?
BioCryst Pharmaceuticals (BCRX) reported payment, tax withholding, share-based payment arrangement of $1.19M in Q1 2026.
How has BioCryst Pharmaceuticals's payment, tax withholding, share-based payment arrangement changed year-over-year?
BioCryst Pharmaceuticals's payment, tax withholding, share-based payment arrangement decreased by 12.1% year-over-year, from $1.35M to $1.19M.
What does payment, tax withholding, share-based payment arrangement mean?
Cash payments made by the company to tax authorities on behalf of employees to satisfy statutory tax withholding obligations related to the vesting or exercise of equity awards. This reflects the cash impact of managing employee equity compensation programs.